Joaquim Bellmunt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8295683/publications.pdf

Version: 2024-02-01

543 papers	44,809 citations	6606 79 h-index	2330 199 g-index
557 all docs	557 docs citations	557 times ranked	34034 citing authors

#	Article	IF	Citations
1	Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 27-34.	0.8	4
2	Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy. Clinical Genitourinary Cancer, 2022, 20, 132-138.	0.9	8
3	Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 272.e1-272.e9.	0.8	16
4	Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder. Expert Review of Anticancer Therapy, 2022, 22, 259-267.	1.1	1
5	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. Journal of Clinical Oncology, 2022, 40, 569-569.	0.8	0
6	TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy.. Journal of Clinical Oncology, 2022, 40, TPS582-TPS582.	0.8	6
7	Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.. Journal of Clinical Oncology, 2022, 40, 519-519.	0.8	0
8	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of Clinical Oncology, 2022, 40, 1772-1782.	0.8	9
9	Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.. Journal of Clinical Oncology, 2022, 40, 516-516.	0.8	0
10	Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.. Journal of Clinical Oncology, 2022, 40, TPS588-TPS588.	0.8	3
11	Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.. Journal of Clinical Oncology, 2022, 40, 512-512.	0.8	2
12	Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?. Drugs and Aging, 2022, 39, 271-284.	1.3	3
13	Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
14	Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. Critical Reviews in Oncology/Hematology, 2022, 174, 103683.	2.0	12
15	Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. Future Oncology, 2022, 18, 2361-2371.	1.1	4
16	Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis. British Journal of Cancer, 2022, 127, 313-320.	2.9	13
17	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	3.2	21
18	Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncology, 2022, 18, 2599-2614.	1.1	10

#	Article	IF	Citations
19	Defining â€œplatinum-ineligibleâ€•patients with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2022, 40, 4577-4577.	0.8	17
20	Health-related quality of life (HRQoL) for patients with advanced/metastatic urothelial carcinoma (UC) enrolled in KEYNOTE-052 who are potentially platinum ineligible.. Journal of Clinical Oncology, 2022, 40, 4561-4561.	0.8	1
21	Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.. Journal of Clinical Oncology, 2022, 40, 4560-4560.	0.8	5
22	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.. Journal of Clinical Oncology, 2022, 40, 4559-4559.	0.8	5
23	Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. European Urology, 2021, 79, 635-654.	0.9	102
24	Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655â€“6. European Urology, 2021, 79, 657-658.	0.9	1
25	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. European Urology Oncology, 2021, 4, 502-505.	2.6	5
26	Cytotoxic Chemotherapy for Advanced Bladder and Upper Tract Cancer. , 2021, , 289-304.		0
27	Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. Current Oncology Reports, 2021, 23, 24.	1.8	5
28	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. Journal of Urology, 2021, 205, 414-419.	0.2	3
29	Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens.. Journal of Clinical Oncology, 2021, 39, 459-459.	0.8	0
30	Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.. Journal of Clinical Oncology, 2021, 39, 438-438.	0.8	13
31	TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.. Journal of Clinical Oncology, 2021, 39, TPS498-TPS498.	0.8	21
32	A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).. Journal of Clinical Oncology, 2021, 39, TPS504-TPS504.	0.8	20
33	Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinneyâ€™s Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol 2021;79:428â€“9. European Urology, 2021, 79, e119-e120.	0.9	0
34	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 525-537.	5.1	225
35	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. Clinical Genitourinary Cancer, 2021, 19, 125-134.	0.9	4
36	Pembrolizumab (pembro) versus investigatorâ€™s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.. Journal of Clinical Oncology, 2021, 39, 4532-4532.	0.8	32

#	Article	IF	Citations
37	Metastatic urothelial carcinoma. Cancer Cell, 2021, 39, 583-585.	7.7	5
38	Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.. Journal of Clinical Oncology, 2021, 39, 4525-4525.	0.8	3
39	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.. Journal of Clinical Oncology, 2021, 39, 4520-4520.	0.8	8
40	Advances in the management of urothelial carcinoma: is immunotherapy the answer?. Expert Opinion on Pharmacotherapy, 2021, 22, 1743-1759.	0.9	3
41	First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.. Journal of Clinical Oncology, 2021, 39, 4508-4508.	0.8	21
42	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treatment Reviews, 2021, 97, 102187.	3.4	31
43	Current Therapy for Metastatic Urothelial Carcinoma. Hematology/Oncology Clinics of North America, 2021, 35, 469-493.	0.9	4
44	Adjuvant immunotherapy in muscle-invasive urothelial carcinoma â€“ Author's reply. Lancet Oncology, The, 2021, 22, e238.	5.1	3
45	ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature, 2021, 595, 432-437.	13.7	293
46	Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era. Minerva Urology and Nephrology, 2021, 73, 292-298.	1.3	11
47	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist, 2021, 26, 1026-1034.	1.9	8
48	SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence. Prostate, 2021, 81, 1267-1277.	1.2	7
49	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. Journal of Clinical Investigation, 2021, 131, .	3.9	17
50	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 5775.	5.8	59
51	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nature Medicine, 2021, 27, 2200-2211.	15.2	65
52	Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma. Cancers, 2021, 13, 6235.	1.7	2
53	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. European Urology Oncology, 2020, 3, 671-679.	2.6	11
54	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. European Urology Oncology, 2020, 3, 94-101.	2.6	41

#	Article	IF	Citations
55	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	0.9	741
56	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. International Journal of Clinical Oncology, 2020, 25, 165-174.	1.0	27
57	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treatment Reviews, 2020, 82, 101925.	3.4	73
58	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. British Journal of Cancer, 2020, 122, 555-563.	2.9	59
59	Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology, 2020, 13, 1-6.	1.3	63
60	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€"An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	0.9	132
61	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 2020, 38, 4064-4075.	0.8	78
62	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 934.e1-934.e9.	0.8	2
63	Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in firstâ€line metastatic renal carcinoma (SUNRISES study). BJU International, 2020, 126, 559-567.	1.3	5
64	Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. Scientific Reports, 2020, 10, 20135.	1.6	4
65	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Nonâ€"Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 4476-4486.	0.4	49
66	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2020, 21, 1574-1588.	5.1	324
67	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2020, 383, 1218-1230.	13.9	802
68	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research, 2020, 26, 6122-6131.	3.2	9
69	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2020, 38, 2658-2666.	0.8	186
70	Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. , 2020, 8, e000419.		7
71	FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols, 2020, 15, 2503-2518.	5.5	20
72	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. Clinical Genitourinary Cancer, 2020, 18, e543-e556.	0.9	22

#	Article	IF	Citations
73	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434â€“5. European Urology, 2020, 77, 436-438.	0.9	1
74	Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. European Urology Oncology, 2020, 3, 351-359.	2.6	31
75	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology, 2020, 38, 5000-5000.	0.8	43
76	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.. Journal of Clinical Oncology, 2020, 38, TPS5095-TPS5095.	0.8	9
77	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. Journal of Clinical Oncology, 2020, 38, LBA1-LBA1.	0.8	64
78	FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression.. Journal of Clinical Oncology, 2020, 38, 489-489.	0.8	32
79	FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.. Journal of Clinical Oncology, 2020, 38, TPS590-TPS590.	0.8	7
80	Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2020, 38, 467-467.	0.8	0
81	Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens.. Journal of Clinical Oncology, 2020, 38, e17005-e17005.	0.8	0
82	Clinical outcomes and economic burden for bladder cancer patients: An analysis from a Swedish cancer registry.. Journal of Clinical Oncology, 2020, 38, 5026-5026.	0.8	3
83	Editorial Comment. Journal of Urology, 2020, 204, 69-70.	0.2	0
84	Abstract 3662: FiTAc-seq: Fixed-Tissue ChIP-seq for H3K27Ac profiling and super-enhancer analysis on FFPE tissues. , 2020, , .		0
85	266â€…Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC). , 2020, , .		3
86	ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 977-988.	3.2	104
87	Does it matter whether a T1 high-grade tumor is molecularly classified?. European Urology Oncology, 2019, 4, 837-842.	2.6	1
88	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. European Urology, 2019, 76, 425-429.	0.9	15
89	Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?. European Urology Oncology, 2019, 2, 597-602.	2.6	15
90	SIUâ€“ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 61-83.	1.2	40

#	Article	IF	Citations
91	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 368-380.	0.9	48
92	Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3KÎ± Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Molecular Cancer Research, 2019, 17, 1931-1944.	1.5	23
93	SPOPandFOXA1mutations are associated with PSA recurrence inERGwt tumors, andSPOPdownregulation withERGâ€rearranged prostate cancer. Prostate, 2019, 79, 1156-1165.	1.2	12
94	Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 457-466.	1.4	5
95	Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities. Nature Reviews Urology, 2019, 16, 433-445.	1.9	24
96	Immunotherapy in non-metastatic urothelial cancer: back to the â€˜futureâ€™. Expert Opinion on Biological Therapy, 2019, 19, 685-695.	1.4	3
97	The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. European Urology, 2019, 75, 961-964.	0.9	141
98	Management of metastatic bladder cancer. Cancer Treatment Reviews, 2019, 76, 10-21.	3.4	190
99	Treatment of Metastatic Urothelial Cancer in 2018. JAMA Oncology, 2019, 5, 904.	3.4	2
100	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2â€“4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. European Urology Oncology, 2019, 2, 248-256.	2.6	11
101	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist, 2019, 24, 1348-1355.	1.9	10
102	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 7-14.e3.	0.9	9
103	Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2019, 103, 344-352.	0.4	5
104	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clinical Cancer Research, 2019, 25, 2458-2470.	3.2	102
105	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 2019, 125, 533-540.	2.0	38
106	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European Urology Focus, 2019, 5, 242-249.	1.6	11
107	KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)â€” Updated response and survival results.. Journal of Clinical Oncology, 2019, 37, 4546-4546.	0.8	19
108	A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).. Journal of Clinical Oncology, 2019, 37, TPS499-TPS499.	0.8	6

#	Article	IF	Citations
109	Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, 478-478.	0.8	2
110	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.. Journal of Clinical Oncology, 2019, 37, 4535-4535.	0.8	0
111	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. Journal of Clinical Oncology, 2019, 37, e16017-e16017.	0.8	0
112	A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).. Journal of Clinical Oncology, 2019, 37, TPS4590-TPS4590.	0.8	0
113	Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma. Cancer Research, 2019, 79, CT177-CT177.	0.4	1
114	Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology. , 2019, , .		0
115	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. European Urology, 2018, 73, 800-806.	0.9	26
116	Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer. JAMA Oncology, 2018, 4, 537.	3.4	104
117	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	0.8	52
118	Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. Journal of Urology, 2018, 199, 1149-1157.	0.2	28
119	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clinical Genitourinary Cancer, 2018, 16, e961-e967.	0.9	14
120	Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptorâ€“Targeted Agents. Clinical Genitourinary Cancer, 2018, 16, e777-e784.	0.9	20
121	Avelumab for the treatment of urothelial cancer. Expert Review of Anticancer Therapy, 2018, 18, 421-429.	1.1	9
122	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. European Urology, 2018, 73, 40-50.	0.9	107
123	Exploring Patterns of Mitomycin C Use in Community Practice Urology. Urology Practice, 2018, 5, 7-14.	0.2	2
124	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologistâ€™s Perspective from a Multicentre Study. European Urology Focus, 2018, 4, 937-945.	1.6	7
125	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer, 2018, 16, e483-e490.	0.9	12
126	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e129-e139.	0.9	17

#	Article	IF	Citations
127	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta OncolÃ³gica, 2018, 57, 491-497.	0.8	22
128	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2018, 4, 225.	3.4	58
129	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clinical Genitourinary Cancer, 2018, 16, e161-e167.	0.9	3
130	Changes in expectations for metastatic urothelial carcinoma. Nature Reviews Clinical Oncology, 2018, 15, 73-74.	12.5	2
131	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	0.9	62
132	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 1579-1587.	0.8	97
133	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11.	1.5	2
134	Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusionâ€“Positive Metastatic Urothelial Carcinoma. JCO Precision Oncology, 2018, 2, 1-6.	1.5	0
135	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Frontiers in Oncology, 2018, 8, 463.	1.3	27
136	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer, 2018, 119, 707-712.	2.9	28
137	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. Journal of Urology, 2018, 200, 1207-1214.	0.2	26
138	The Cancer Genome Atlas Project in Bladder Cancer. Cancer Treatment and Research, 2018, 175, 259-271.	0.2	16
139	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer, 2018, 118, 1434-1441.	2.9	34
140	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factorâ€“Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research, 2018, 24, 4081-4088.	3.2	24
141	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncology, The, 2018, 19, e317-e326.	5.1	46
142	Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis. Quality of Life Research, 2018, 27, 2759-2775.	1.5	16
143	Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4. Biomedicines, 2018, 6, 85.	1.4	25
144	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clinical Cancer Research, 2018, 24, 6115-6124.	3.2	14

#	Article	IF	Citations
145	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	0.9	61
146	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200
147	Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 469.e1-469.e11.	0.8	37
148	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281.	9.4	438
149	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology, 2018, 1, 83-90.	2.6	59
150	Pembrolizumab (pembro) versus investigatorâ€™s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.. Journal of Clinical Oncology, 2018, 36, 4521-4521.	0.8	6
151	Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2018, 36, 4524-4524.	0.8	36
152	FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).. Journal of Clinical Oncology, 2018, 36, 4534-4534.	0.8	17
153	First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts).. Journal of Clinical Oncology, 2018, 36, e16517-e16517.	0.8	3
154	Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.. Journal of Clinical Oncology, 2018, 36, TPS4586-TPS4586.	0.8	5
155	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigatorâ€™s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2018, 36, 410-410.	0.8	19
156	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. Journal of Clinical Oncology, 2018, 36, 413-413.	0.8	10
157	Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.. Journal of Clinical Oncology, 2018, 36, 426-426.	0.8	3
158	Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2018, 36, 451-451.	0.8	1
159	Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.. Journal of Clinical Oncology, 2018, 36, 448-448.	0.8	0
160	FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians.. Journal of Clinical Oncology, 2018, 36, 465-465.	0.8	0
161	Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.. Journal of Clinical Oncology, 2018, 36, 4539-4539.	0.8	0
162	Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.. Journal of Clinical Oncology, 2018, 36, 4535-4535.	0.8	0

#	Article	IF	Citations
163	Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.. Journal of Clinical Oncology, 2018, 36, 3036-3036.	0.8	1
164	Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2018, 36, 4529-4529.	0.8	0
165	Comprehensive genomic characterization of urothelial carcinomas.. Journal of Clinical Oncology, 2018, 36, 4527-4527.	0.8	0
166	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World Journal of Urology, 2017, 35, 327-335.	1.2	26
167	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80
168	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncology, The, 2017, 18, 212-220.	5.1	307
169	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	0.8	104
170	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	3.2	225
171	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Medicine, 2017, 6, 186-194.	1.3	12
172	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. European Urology, 2017, 72, 84-109.	0.9	348
173	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist, 2017, 22, 286-292.	1.9	54
174	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	13.9	2,677
175	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research, 2017, 5, 312-318.	1.6	354
176	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clinical Genitourinary Cancer, 2017, 15, 509-512.e9.	0.9	1
177	PD62-12 COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR LOCALIZED MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER. Journal of Urology, 2017, 197, .	0.2	0
178	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	0.9	110
179	Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs, 2017, 77, 1077-1089.	4.9	67
180	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology, 2017, 198, 817-823.	0.2	31

#	Article	IF	Citations
181	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	0.9	40
182	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. European Urology, 2017, 72, 250-266.	0.9	305
183	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA;) Tj ETQq1 1 0.784314 rgBT /Overlock 2017, 18, 672-681a.	5.1	49
184	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	6.3	1,728
185	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European Urology, 2017, 71, 281-289.	0.9	56
186	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	13.5	1,742
187	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 1483-1492.	5.1	1,034
188	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Nonâ€“Lymph Node Distant Metastasis. Clinical Genitourinary Cancer, 2017, 15, e1089-e1094.	0.9	3
189	Antiangiogenesis to curb urothelial cancer. Lancet, The, 2017, 390, 2220-2221.	6.3	4
190	â€˜Working toward understanding oligo and polymetastatic prostate cancerâ€™. Current Opinion in Urology, 2017, 27, 532.	0.9	0
191	New treatment options for metastatic renal cell carcinoma. ESMO Open, 2017, 2, e000185.	2.0	60
192	Neoadjuvant chemotherapy prior to radical cystectomy for muscleâ€invasive bladder cancer with variant histology. Cancer, 2017, 123, 4346-4355.	2.0	138
193	MP34-11 NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY. Journal of Urology, 2017, 197, .	0.2	2
194	PD57-03 ASSESSMENT OF THE ECOLOGICAL ASSOCIATION BETWEEN TOBACCO SMOKING EXPOSURE AND BLADDER CANCER INCIDENCE OVER THE PAST HALF-CENTURY IN THE UNITED STATES. Journal of Urology, 2017, 197, .	0.2	0
195	MP34-19 EFFECT OF HISTOLOGICAL VARIANTS ON THE OUTCOMES OF RADICAL CYSTECTOMY FOR NON-METASTATIC MUSCLE-INVASIVE URINARY BLADDER CANCER. Journal of Urology, 2017, 197, .	0.2	0
196	PD67-09 COMPARATIVE EFFECTIVNESS OF ROBOT-ASSISTED VS. OPEN RADICAL CYSTECTOMY. Journal of Urology, 2017, 197, .	0.2	0
197	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. European Urology, 2017, 72, 869-885.	0.9	182
198	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 120, 120-126.	2.0	19

#	Article	IF	Citations
199	Pembrolizumab in the treatment of advanced urothelial cancer. Future Oncology, 2017, 13, 2745-2758.	1.1	4
200	The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review. Cancer Treatment Reviews, 2017, 61, 82-93.	3.4	21
201	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU International, 2017, 119, 579-584.	1.3	16
202	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. European Urology, 2017, 71, 168-171.	0.9	48
203	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. JAMA Oncology, 2017, 3, 68.	3.4	33
204	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2017, 71, 618-629.	0.9	2,497
205	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. European Urology, 2017, 71, 630-642.	0.9	1,215
206	The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 755-760.	0.7	17
207	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer, 2017, 15, 23-30.e2.	0.9	50
208	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications, 2017, 8, 2193.	5.8	99
209	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer, 2017, 3, 145-146.	0.2	8
210	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. , 2017, 5, 68.		68
211	A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma. Case Reports in Oncology, 2017, 10, 493-500.	0.3	1
212	Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget, 2017, 8, 84572-84578.	0.8	66
213	Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas.. Journal of Clinical Oncology, 2017, 35, 4500-4500.	0.8	4
214	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 4501-4501.	0.8	17
215	Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 4502-4502.	0.8	49
216	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.. Journal of Clinical Oncology, 2017, 35, 4530-4530.	0.8	6

#	Article	IF	Citations
217	Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 4540-4540.	0.8	8
218	Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study.. Journal of Clinical Oncology, 2017, 35, 5042-5042.	0.8	2
219	Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.. Journal of Clinical Oncology, 2017, 35, TPS4590-TPS4590.	0.8	36
220	Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.. Journal of Clinical Oncology, 2017, 35, 282-282.	0.8	6
221	Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.. Journal of Clinical Oncology, 2017, 35, 284-284.	0.8	42
222	Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study.. Journal of Clinical Oncology, 2017, 35, 290-290.	0.8	9
223	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 305-305.	0.8	63
224	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis.. Journal of Clinical Oncology, 2017, 35, 332-332.	0.8	1
225	Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.. Journal of Clinical Oncology, 2017, 35, 346-346.	0.8	2
226	A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).. Journal of Clinical Oncology, 2017, 35, 285-285.	0.8	0
227	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Safety analysis from an expanded access study.. Journal of Clinical Oncology, 2017, 35, 4532-4532.	0.8	0
228	Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2017, 35, 4512-4512.	0.8	0
229	Prognostic impact of primary tumor location in advanced urothelial carcinoma: The EORTC series.. Journal of Clinical Oncology, 2017, 35, e16034-e16034.	0.8	0
230	Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.. Journal of Clinical Oncology, 2017, 35, e16012-e16012.	0.8	0
231	Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis.. Journal of Clinical Oncology, 2017, 35, e16001-e16001.	0.8	0
232	Abstract 2918: Analysis of matched pre and post cisplatin-treated muscle-invasive bladder cancer reveals a candidate cisplatin mutational signature. , 2017, , .		0
233	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factorâ€targeted therapies. Cancer, 2016, 122, 2389-2398.	2.0	16
234	Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, FernÃ¡ndez PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127â€“136. European Journal of Cancer, 2016, 68, 196-197.	1.3	0

#	Article	IF	Citations
235	PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA. Journal of Urology, 2016, 195, .	0.2	0
236	MP63-06 RACIAL DISPARITIES IN QUALITY METRICS OF MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2016, 195, .	0.2	0
237	Urothelial carcinoma management in elderly or unfit patients. European Journal of Cancer, Supplement, 2016, 14, 1-20.	2.2	45
238	Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970â€“7. European Urology, 2016, 70, e71.	0.9	5
239	Angiogenesis as a therapeutic target in urothelial carcinoma. Nature Reviews Urology, 2016, 13, 306-307.	1.9	17
240	Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nature Medicine, 2016, 22, 685-691.	15.2	64
241	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Scientific Reports, 2016, 6, 27702.	1.6	46
242	Patterns of Bladder Preservation TherapyÂUtilization for Muscle-Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 405-413.	0.2	12
243	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.2	30
244	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 820-824.	2.3	36
245	Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open, 2016, 1, e000126.	2.0	59
246	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts. , 2016, 4, .		14
247	Cancer immunotherapy. Current Opinion in Urology, 2016, 26, 556-563.	0.9	5
248	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€“Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	0.8	70
249	Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncology, 2016, 2, 1094.	3.4	205
250	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. British Journal of Cancer, 2016, 115, 12-19.	2.9	9
251	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clinical Genitourinary Cancer, 2016, 14, e299-e305.	0.9	11
252	Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. European Urology, 2016, 69, 802-820.	0.9	75

#	Article	IF	Citations
253	Radiologic Heterogeneity in Responses to Antiâ€“PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 12-17.	1.6	49
254	The evolving role of enzalutamide on the treatment of prostate cancer. Future Oncology, 2016, 12, 607-616.	1.1	7
255	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	3.2	193
256	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 352-359.	0.9	34
257	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	6.3	3,077
258	Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?. European Urology, 2016, 69, 574-575.	0.9	0
259	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. European Urology, 2016, 69, 634-641.	0.9	53
260	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. European Urology, 2016, 69, 924-932.	0.9	22
261	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 624-633.	0.9	25
262	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. Journal of Urology, 2016, 195, 277-282.	0.2	54
263	Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer â€” At What Cost? Eur Urol 2016;69:642â€“44. European Urology, 2016, 69, 644-645.	0.9	0
264	PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).. Journal of Clinical Oncology, 2016, 34, 104-104.	0.8	32
265	Genomic evolution in muscle-invasive bladder cancer resistant to neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2016, 34, 4518-4518.	0.8	1
266	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2016, 34, 4524-4524.	0.8	6
267	Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)â€”SOGUG 2011-02.. Journal of Clinical Oncology, 2016, 34, 4529-4529.	0.8	2
268	An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel.. Journal of Clinical Oncology, 2016, 34, e16509-e16509.	0.8	1
269	A phase 3 study of first-line durvalumab (MEDI4736) Â± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.. Journal of Clinical Oncology, 2016, 34, TPS4574-TPS4574.	0.8	12
270	KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).. Journal of Clinical Oncology, 2016, 34, TPS4576-TPS4576.	0.8	11

#	Article	IF	Citations
271	IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2016, 34, 355-355.	0.8	45
272	Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors.. Journal of Clinical Oncology, 2016, 34, 385-385.	0.8	1
273	Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project.. Journal of Clinical Oncology, 2016, 34, 405-405.	0.8	1
274	Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT).. Journal of Clinical Oncology, 2016, 34, 422-422.	0.8	1
275	Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.. Journal of Clinical Oncology, 2016, 34, 73-73.	0.8	5
276	Chemotherapy treatment patterns and survival outcomes in patients with visceral metastatic upper tract urothelial cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 415-415.	0.8	0
277	Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report.. Journal of Clinical Oncology, 2016, 34, 450-450.	0.8	0
278	Genomic alterations in upper tract urothelial carcinoma (UTUC) versus urothelial carcinoma of the bladder (UBC).. Journal of Clinical Oncology, 2016, 34, 431-431.	0.8	0
279	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2016, 34, 386-386.	0.8	0
280	A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.. Journal of Clinical Oncology, 2016, 34, 201-201.	0.8	2
281	Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.. Journal of Clinical Oncology, 2016, 34, 33-33.	0.8	0
282	Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2016, 34, 442-442.	0.8	0
283	The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT).. Journal of Clinical Oncology, 2016, 34, e16026-e16026.	0.8	0
284	Genomic landscape of micropapillary nonmuscle-invasive bladder cancer.. Journal of Clinical Oncology, 2016, 34, e16028-e16028.	0.8	0
285	Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2016, 34, e16129-e16129.	0.8	0
286	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. Journal of Clinical Oncology, 2016, 34, 4535-4535.	0.8	0
287	Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2016, 34, 4536-4536.	0.8	0
288	Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.. Journal of Clinical Oncology, 2016, 34, 3068-3068.	0.8	0

#	Article	IF	Citations
289	Fixed tissue ChIP-seq (FiT-Seq) of archived FFPE clinical bladder cancer (BC) samples to reveal tumor-specific enhancer and super-enhancer profiles.. Journal of Clinical Oncology, 2016, 34, 4541-4541.	0.8	0
290	Genomic predictors of recurrence (R) or progression (P) in high grade T1 (HGT1) non-muscle invasive (NMI) bladder cancer.. Journal of Clinical Oncology, 2016, 34, 4539-4539.	0.8	1
291	Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project. , 2016, , .		0
292	MP68-11 A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED UROTHELIAL CANCER. Journal of Urology, 2015, 193, .	0.2	4
293	<scp>HER2</scp> as a target in invasive urothelial carcinoma. Cancer Medicine, 2015, 4, 844-852.	1.3	41
294	Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). , 2015, 3, .		12
295	The effect of smoking on prostate cancer survival. European Journal of Cancer Prevention, 2015, 24, 335-339.	0.6	13
296	Reply to K. Lu. Journal of Clinical Oncology, 2015, 33, 2716-2717.	0.8	0
297	Is angiogenesis still an attractive target in metastatic castrationâ€resistant prostate cancer?. BJU International, 2015, 116, 500-501.	1.3	3
298	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
299	Diagnosis of Bladder Carcinoma. Surgical Pathology Clinics, 2015, 8, 677-685.	0.7	17
300	Enzalutamide in European and North American men participating in the AFFIRM trial. BJU International, 2015, 115, 41-49.	1.3	13
301	Incidental focal uptake in colorectal location on oncologic FDG PET and PET/CT studies: Histopathological findings and clinical significances. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 95-101.	0.0	8
302	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy forÂUrothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 185-192.	0.9	2
303	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 2157-2166.	3.2	227
304	Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. Journal of Clinical Oncology, 2015, 33, 643-650.	0.8	165
305	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. Journal of Clinical Oncology, 2015, 33, 723-731.	0.8	127
306	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. Clinical Genitourinary Cancer, 2015, 13, 178-184.	0.9	15

#	Article	IF	Citations
307	Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301. European Urology, 2015, 67, 866-873.	0.9	49
308	Salvage Systemic Therapy for Advanced Urothelial Carcinoma: On the Cusp of a Sea Change?. Oncologist, 2015, 20, 461-463.	1.9	4
309	Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU International, 2015, 115, 854-855.	1.3	4
310	Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, xiii-xiv.	0.9	8
311	Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2015, 15, 151-156.	1.1	11
312	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. European Urology, 2015, 67, 904-912.	0.9	18
313	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer, 2015, 15, 242.	1.1	25
314	A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treatment Reviews, 2015, 41, 310-319.	3.4	40
315	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 417-425.	5.1	137
316	Perioperative Therapy for Muscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 301-318.	0.9	5
317	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscleâ€invasive bladder cancer. Cancer, 2015, 121, 2586-2593.	2.0	155
318	Incomplete Cross-Resistance Between Taxanes forÂAdvanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clinical Genitourinary Cancer, 2015, 13, 250-256.	0.9	5
319	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	0.8	21
320	Future Directions and Targeted Therapies in Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 361-376.	0.9	22
321	The â€œArtificialâ€•Docetaxel Space: The Evolving Treatment Paradigm of Metastatic Castration-Resistant Prostate Cancer. European Urology, 2015, 67, 30-32.	0.9	3
322	Impact of surgeon volume on the morbidity and costs of radical cystectomy in the <scp>USA</scp>: a contemporary populationâ€based analysis. BJU International, 2015, 115, 713-721.	1.3	79
323	A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2015, 33, 4501-4501.	0.8	43
324	Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.. Journal of Clinical Oncology, 2015, 33, 4502-4502.	0.8	64

#	Article	IF	Citations
325	First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.. Journal of Clinical Oncology, 2015, 33, 4503-4503.	0.8	5
326	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. Journal of Clinical Oncology, 2015, 33, 4519-4519.	0.8	1
327	Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC).. Journal of Clinical Oncology, 2015, 33, 4524-4524.	0.8	2
328	Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): Preliminary analysis of a randomized placebo controlled phase II trial (MAJA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 617 T	0.8	
329	Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma.. Journal of Clinical Oncology, 2015, 33, 4532-4532.	0.8	2
330	A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. Journal of Clinical Oncology, 2015, 33, 4559-4559.	0.8	2
331	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.. Journal of Clinical Oncology, 2015, 33, TPS4571-TPS4571.	0.8	7
332	KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.. Journal of Clinical Oncology, 2015, 33, TPS4572-TPS4572.	0.8	9
333	A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes.. Journal of Clinical Oncology, 2015, 33, TPS4575-TPS4575.	0.8	4
334	Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study.. Journal of Clinical Oncology, 2015, 33, 296-296.	0.8	23
335	Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study.. Journal of Clinical Oncology, 2015, 33, 297-297.	0.8	9
336	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. Journal of Clinical Oncology, 2015, 33, 311-311.	0.8	1
337	Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT).. Journal of Clinical Oncology, 2015, 33, 318-318.	0.8	1
338	miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel.. Journal of Clinical Oncology, 2015, 33, 364-364.	0.8	1
339	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 422-422.	0.8	1
340	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS ONE, 2015, 10, e0124711.	1.1	16
341	Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).. Journal of Clinical Oncology, 2015, 33, 365-365.	0.8	0
342	A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity.. Journal of Clinical Oncology, 2015, 33, 15-15.	0.8	1

#	Article	IF	Citations
343	Genomic landscape of high-grade T1 micropapillary bladder tumors.. Journal of Clinical Oncology, 2015, 33, 299-299.	0.8	0
344	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinium-based chemotherapy: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2015, 33, 351-351.	0.8	0
345	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.. Journal of Clinical Oncology, 2015, 33, 369-369.	0.8	0
346	Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients.. Journal of Clinical Oncology, 2015, 33, 4530-4530.	0.8	0
347	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2015, 33, 4527-4527.	0.8	0
348	Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy.. Journal of Clinical Oncology, 2015, 33, e15518-e15518.	0.8	0
349	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.. Journal of Clinical Oncology, 2015, 33, e15520-e15520.	0.8	0
350	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. Journal of Clinical Oncology, 2015, 33, 4560-4560.	0.8	0
351	Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC).. Journal of Clinical Oncology, 2015, 33, e15519-e15519.	0.8	0
352	Contemporary use of lymph node dissection at nephroureterectomy in treating upper tract urothelial carcinoma: A US population-based analysis.. Journal of Clinical Oncology, 2015, 33, e15634-e15634.	0.8	0
353	Abstract 3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. , 2015, , .		0
354	Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE, 2014, 9, e103325.	1.1	9
355	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 2014, 9, e86263.	1.1	76
356	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	3.2	63
357	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. Journal of Clinical Oncology, 2014, 32, 4171-4172.	0.8	1
358	Sunitinib malate in the treatment of urothelial cancer. Expert Opinion on Investigational Drugs, 2014, 23, 115-124.	1.9	4
359	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine, 2014, 3, 835-844.	1.3	76
360	Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with firstâ€line sunitinib: a medical chart review across ten centers in five European countries. Cancer Medicine, 2014, 3, 1517-1526.	1.3	53

#	Article	IF	Citations
361	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014, 515, 558-562.	13.7	2,109
362	Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer. BJU International, 2014, 114, 163-164.	1.3	1
363	A nomogram including baseline prognostic factors to estimate the activity of secondâ€line therapy for advanced urothelial carcinoma. BJU International, 2014, 113, E137-43.	1.3	31
364	In Reply. Oncologist, 2014, 19, 305-305.	1.9	0
365	Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma. Oncologist, 2014, 19, 917-918.	1.9	4
366	Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncology, 2014, 10, 351-362.	1.1	7
367	Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. European Urology, 2014, 66, 42-54.	0.9	349
368	Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. European Urology, 2014, 66, 569-576.	0.9	205
369	MP13-14 THE IMPACT OF SURGEON VOLUME ON THE MORBIDITY AND COSTS OF NEPHROURETERECTOMY IN THE UNITED STATES: AÂCONTEMPORARY POPULATION-BASED ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
370	Controversies in renal cell carcinoma: Treatment choice after progression on vascular endothelial growth factor-targeted therapy. European Journal of Cancer, 2014, 50, 1321-1329.	1.3	31
371	MP65-14 PROPOSAL FOR INCLUDING SUBSTAGING OF HGT1 BLADDER CANCER IN THE TNM CLASSIFICATION: A SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON 2678 PATIENTS. Journal of Urology, 2014, 191, .	0.2	0
372	MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÃVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302. Journal of Urology, 2014, 191, .	0.2	1
373	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. Clinical Genitourinary Cancer, 2014, 12, 262-269.	0.9	9
374	MP65-12 AN OPTIMIZED TREATMENT STRATEGY FOR HGT1 BLADDER CANCER BASED ON MICROSTAGING: RESULTS AT 5YEARS FOLLOW-UP IN 200 PATIENTS. Journal of Urology, 2014, 191, .	0.2	1
375	The evolving understanding of microRNA in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 41.e31-41.e40.	0.8	65
376	Phase II clinical trial of PM00104 (ZalypsisÂ®) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemotherapy and Pharmacology, 2014, 73, 857-867.	1.1	5
377	New Treatments for Bladder Cancer: When Will We Make Progress?. Current Treatment Options in Oncology, 2014, 15, 99-114.	1.3	16
378	New agents for prostate cancer. Annals of Oncology, 2014, 25, 1700-1709.	0.6	51

#	Article	IF	Citations
379	Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial. Journal of Clinical Oncology, 2014, 32, 752-759.	0.8	179
380	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. European Urology, 2014, 65, 467-479.	0.9	1,304
381	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intentâ€"Update 2013. European Urology, 2014, 65, 124-137.	0.9	1,613
382	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	0.8	229
383	Reply from Authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a Systematic Review and Meta-analysis of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol 2014;66:55â€"6. European Urology, 2014, 66, 57-58.	0.9	3
384	MP61-09 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN AND ROBOT-ASSISTED RADICAL CYSTECTOMIES: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES. Journal of Urology, 2014, 191, .	0.2	2
385	MP13-13 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN VS. MINIMALLY INVASIVE RADICAL NEPHROURETERECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES. Journal of Urology, 2014, 191, .	0.2	1
386	A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma. European Urology, 2014, 66, 529-541.	0.9	205
387	MP56-02 PROGNOSTIC FACTORS FOR HIGH-GRADE T1 BLADDER CANCER: A META-ANALYSIS BASED ON 7,486 PATIENTS. Journal of Urology, 2014, 191, .	0.2	0
388	Hyponatremia Associated with Worse Outcomes in Metastatic Renal Cell Cancer: A Potential Target for Intervention?. European Urology, 2014, 65, 731-732.	0.9	8
389	MP60-14 TRENDS IN URINARY DIVERSION AMONG PATIENTS UNDERGOING RADICAL CYSTECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
390	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 130-137.	0.9	27
391	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer, 2014, 50, 1617-1627.	1.3	133
392	Adrenocortical carcinoma: The management of metastatic disease. Critical Reviews in Oncology/Hematology, 2014, 92, 123-132.	2.0	43
393	Patient Eligibility and Trial Design for the Salvage Therapy ofÂAdvanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 395-398.	0.9	12
394	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. International Journal of Oncology, 2014, 44, 5-16.	1.4	31
395	Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 3526-3526.	0.8	4
396	Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2014, 32, 4512-4512.	0.8	3

#	Article	IF	Citations
397	Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).. Journal of Clinical Oncology, 2014, 32, 4534-4534.	0.8	2
398	PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2014, 32, 4552-4552.	0.8	2
399	Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2014, 32, 5011-5011.	0.8	49
400	Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.. Journal of Clinical Oncology, 2014, 32, 5042-5042.	0.8	2
401	Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.. Journal of Clinical Oncology, 2014, 32, 14-14.	0.8	4
402	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. Journal of Clinical Oncology, 2014, 32, 336-336.	0.8	1
403	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. Journal of Clinical Oncology, 2014, 32, 353-353.	0.8	2
404	Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway and prognostic significance for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial cancer (UC).. Journal of Clinical Oncology, 2014, 32, 358-358.	0.8	1
405	Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)â€"Interim analysis on safety.. Journal of Clinical Oncology, 2014, 32, 359-359.	0.8	3
406	Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).. Journal of Clinical Oncology, 2014, 32, 7-7.	0.8	17
407	Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib.. Journal of Clinical Oncology, 2014, 32, 537-537.	0.8	0
408	Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies.. Journal of Clinical Oncology, 2014, 32, 330-330.	0.8	0
409	Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience.. Journal of Clinical Oncology, 2014, 32, 235-235.	0.8	0
410	External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2014, 32, 4542-4542.	0.8	0
411	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. Journal of Clinical Oncology, 2014, 32, 4514-4514.	0.8	0
412	Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials.. Journal of Clinical Oncology, 2014, 32, e15558-e15558.	0.8	0
413	Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors.. Journal of Clinical Oncology, 2014, 32, 4511-4511.	0.8	0
414	Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results.. Journal of Clinical Oncology, 2014, 32, e16088-e16088.	0.8	0

#	Article	IF	Citations
415	Molecular targets on the horizon for kidney and urothelial cancer. Nature Reviews Clinical Oncology, 2013, 10, 557-570.	12.5	21
416	False Positive 2-18Fluroro-deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients With Disseminated Seminoma and Post-Chemotherapy Residual Masses. Clinical Genitourinary Cancer, 2013, 11, 66-69.	0.9	4
417	A new approach to second-line therapy for urothelial cancer?. Lancet Oncology, The, 2013, 14, 682-684.	5.1	8
418	Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. Journal of Translational Medicine, 2013, 11, 182.	1.8	25
419	What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?. Cancer Treatment Reviews, 2013, 39, 366-374.	3.4	29
420	Combination Therapy in Metastatic Renal Cell Cancer. Seminars in Oncology, 2013, 40, 472-481.	0.8	21
421	Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain. Expert Opinion on Drug Safety, 2013, 12, 455-463.	1.0	3
422	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinomaâ€"Neoadjuvant and Adjuvant Settings. European Urology, 2013, 63, 58-66.	0.9	151
423	Tackling the Bone with Alpha Emitters in Metastatic Castration-resistant Prostate Cancer Patients. European Urology, 2013, 63, 198-200.	0.9	10
424	Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology, 2013, 24, 1141-1162.	0.6	137
425	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncology, The, 2013, 14, 1307-1316.	5.1	205
426	Loss of Sh3gl2/Endophilin A1 Is a Common Event in Urothelial Carcinoma that Promotes Malignant Behavior. Neoplasia, 2013, 15, 749-IN16.	2.3	28
427	Impact of Response to Prior Chemotherapy inÂPatients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications forÂTrial Design. Clinical Genitourinary Cancer, 2013, 11, 495-500.	0.9	20
428	Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. European Urology, 2013, 64, 994-1002.	0.9	30
429	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2013, 87, 80-89.	2.0	63
430	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. European Urology, 2013, 63, 717-723.	0.9	104
431	Management of Castrate Resistant Prostate Cancerâ€"Recent Advances and Optimal Sequence of Treatments. Current Urology Reports, 2013, 14, 174-183.	1.0	16
432	Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB). Oncology, 2013, 85, 208-215.	0.9	39

#	Article	IF	Citations
433	Perspectives on Treatment of Metastatic Castrationâ€Resistant Prostate Cancer. Oncologist, 2013, 18, 775-775.	1.9	0
434	Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. Critical Reviews in Oncology/Hematology, 2013, 88, 357-367.	2.0	4
435	Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Current Opinion in Urology, 2013, 23, 466-471.	0.9	19
436	Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2013, 18, 558-567.	1.9	26
437	Stage II Disease, Elderly Patients, Secondary Neoplasms, and the MOSAIC Trial. Journal of Clinical Oncology, 2013, 31, 1609-1609.	0.8	2
438	Perspectives on Treatment of Metastatic Castrationâ€Resistant Prostate Cancer. Oncologist, 2013, 18, 971-971.	1.9	0
439	A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.. Journal of Clinical Oncology, 2013, 31, 5013-5013.	0.8	12
440	Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 301-301.	0.8	2
441	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. Journal of Clinical Oncology, 2013, 31, LBA8-LBA8.	0.8	30
442	Genomic characterization of metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2013, 31, 247-247.	0.8	1
443	Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 260-260.	0.8	0
444	Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 279-279.	0.8	0
445	Abstract 4066: Loss of Sh3gl2/endophilin A1 is an early event in urothelial carcinoma that regulates malignant behavior.. , 2013, , .		0
446	Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987. Journal of Clinical Oncology, 2012, 30, 1107-1113.	0.8	428
447	Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. Journal of Clinical Oncology, 2012, 30, 191-199.	0.8	613
448	New Perspectives in the Therapy of Castration Resistant Prostate Cancer. Current Drug Targets, 2012, 13, 1676-1686.	1.0	34
449	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2012, 62, 523-533.	0.9	214
450	Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer and Metastasis Reviews, 2012, 31, 11-17.	2.7	14

#	Article	IF	Citations
451	The optimize project: beyond first-line therapy in metastatic renal cell carcinoma. Cancer and Metastasis Reviews, 2012, 31, 1-2.	2.7	0
452	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine, 2012, 18, 221-223.	15.2	434
453	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews, 2012, 38, 127-132.	3.4	9
454	Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treatment Reviews, 2012, 38, 431-441.	3.4	12
455	Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. European Journal of Cancer, 2012, 48, 1495-1502.	1.3	17
456	Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. European Journal of Cancer, 2012, 48, 1816-1821.	1.3	37
457	New Therapeutic Challenges in Advanced Bladder Cancer. Seminars in Oncology, 2012, 39, 598-607.	0.8	100
458	The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients. Current Oncology Reports, 2012, 14, 295-306.	1.8	38
459	Advances in the management of highâ€risk localised and metastatic prostate cancer. BJU International, 2012, 109, 8-13.	1.3	11
460	Practical aspects of metastatic castrationâ€resistant prostate cancer management: patient case studies. BJU International, 2012, 109, 14-19.	1.3	4
461	Current Vaccination Strategies for Prostate Cancer. European Urology, 2012, 61, 290-306.	0.9	35
462	Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature. European Urology, 2012, 62, 290-302.	0.9	121
463	Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Investigational New Drugs, 2012, 30, 729-740.	1.2	36
464	Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel.. Journal of Clinical Oncology, 2012, 30, 250-250.	0.8	2
465	Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy.. Journal of Clinical Oncology, 2012, 30, 291-291.	0.8	0
466	Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opinion on Drug Safety, 2011, 10, 645-653.	1.0	37
467	Management of Treatment-Related Toxicity with Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices. Hematology/Oncology Clinics of North America, 2011, 25, 893-915.	0.9	21
468	What are the expected developments in the medical treatment of bladder cancer. European Journal of Cancer, 2011, 47, S294-S297.	1.3	0

#	Article	IF	Citations
469	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncology, The, 2011, 12, 211-214.	5.1	261
470	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncology, The, 2011, 12, 1143-1150.	5.1	217
471	Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. ClinicoEconomics and Outcomes Research, 2011, 3, 19.	0.7	5
472	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferonâ€Ì±2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU International, 2011, 107, 214-219.	1.3	43
473	A new patientâ€focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU International, 2011, 107, 1190-1199.	1.3	21
474	Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU International, 2011, 107, 1-12.	1.3	1
475	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. European Urology, 2011, 59, 61-71.	0.9	1,299
476	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. European Urology, 2011, 59, 526-540.	0.9	119
477	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. European Urology, 2011, 59, 572-583.	0.9	459
478	The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2011, 60, 270-278.	0.9	53
479	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. European Urology, 2011, 60, 684-690.	0.9	125
480	Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's Letter to the Editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 2011;59:572â€“83. European Urology, 2011, 60, e39-e41.	0.9	1
481	Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. Medical Oncology, 2011, 28, 1379-1383.	1.2	7
482	Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches. Current Oncology Reports, 2011, 13, 216-221.	1.8	48
483	Experience with sorafenib and adverse event management. Critical Reviews in Oncology/Hematology, 2011, 78, 24-32.	2.0	62
484	Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2011, 29, 632-638.	0.8	259
485	Treatment of Patients With Metastatic Urothelial Cancer â€œUnfitâ€•for Cisplatin-Based Chemotherapy. Journal of Clinical Oncology, 2011, 29, 2432-2438.	0.8	514
486	Experience with sorafenib and the elderly patient. Medical Oncology, 2010, 27, 1359-1370.	1.2	13

#	Article	IF	Citations
487	A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clinical and Translational Oncology, 2010, 12, 503-508.	1.2	9
488	Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer and Metastasis Reviews, 2010, 29, 1-10.	2.7	3
489	Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer and Metastasis Reviews, 2010, 29, 11-20.	2.7	3
490	¹¹Câ€METHIONINE POSITRONâ€EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PETâ€CT) IN EVALUATING METASTATIC TRANSITIONAL CELL CARCINOMA RESPONSE TO SUNITINIB THERAPY. BJU International, 2010, 106, 1249-1250.	1.3	1
491	Reply to G. Sonpavde et al. Journal of Clinical Oncology, 2010, 28, e443-e444.	0.8	8
492	Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. Journal of Clinical Oncology, 2010, 28, 2280-2285.	0.8	400
493	Reply to G. Sonpavde et al. Journal of Clinical Oncology, 2010, 28, e208-e208.	0.8	1
494	Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens. Journal of Clinical Oncology, 2010, 28, 1850-1855.	0.8	340
495	Review: Castration-resistant prostate cancer: new science and therapeutic prospects. Therapeutic Advances in Medical Oncology, 2010, 2, 189-207.	1.4	25
496	Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. Journal of Clinical Oncology, 2010, 28, 2144-2150.	0.8	767
497	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treatment Reviews, 2010, 36, 16-23.	3.4	46
498	Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treatment Reviews, 2010, 36, 416-424.	3.4	89
499	Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 2010, 11, 350-357.	5.1	64
500	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Review of Anticancer Therapy, 2010, 10, 825-835.	1.1	17
501	Abstract 1168: Urothelial cell carcinomas harbor very frequent mutations in FGFR3-PI3K-AKT pathway and highest prevalence of mutations is related to low-grade tumors. , 2010, , .		0
502	Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer â€œUnfitâ€•for Cisplatin-Based Chemotherapy: Phase IIâ€"Results of EORTC Study 30986. Journal of Clinical Oncology, 2009, 27, 5634-5639.	0.8	161
503	The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce. Critical Reviews in Oncology/Hematology, 2009, 69, 64-72.	2.0	93
504	Predictive modelling in hormone-refractory prostate cancer (HRPC). Clinical and Translational Oncology, 2009, 11, 82-85.	1.2	4

#	Article	IF	Citations
505	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 1-13.	1.1	10
506	The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU International, 2009, 103, 572-577.	1.3	39
507	Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU International, 2009, 104, 10-18.	1.3	25
508	EORTC-GU group expert opinion on metastatic renal cell cancer. European Journal of Cancer, 2009, 45, 765-773.	1.3	103
509	Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. European Journal of Cancer, 2009, 45, 2804-2809.	1.3	2
510	Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract. Journal of Clinical Oncology, 2009, 27, 4454-4461.	0.8	687
511	Role of Chemotherapy in Nonmetastatic Hormone-Refractory Prostate Cancer. European Urology Supplements, 2009, 8, 448-452.	0.1	2
512	Advances in the Management of Metastatic Renal Cell Cancer. European Urology Supplements, 2009, 8, 758-761.	0.1	0
513	Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncology, The, 2009, 10, 740.	5.1	4
514	The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival. European Urology, 2008, 54, 1192-1197.	0.9	4
515	Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors. Seminars in Oncology, 2008, 35, S34-S43.	0.8	20
516	The Oncologist's View: Targeted Therapies in Advanced Renal Cell Carcinoma. European Urology Supplements, 2008, 7, 55-62.	0.1	8
517	Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence. European Urology Supplements, 2008, 7, 585-592.	0.1	3
518	Treatment of metastatic cancer. , 2008, , 225-234.		0
519	Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 257-262.	0.8	127
520	Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer. Urology, 2007, 69, 62-79.	0.5	183
521	Current Treatment in Advanced Renal Cell Carcinoma (RCC): Impact of Targeted Therapies in the Management of RCC. European Urology Supplements, 2007, 6, 484-491.	0.1	11
522	The medical management of prostate cancer: a multidisciplinary team approach. BJU International, 2007, 99, 22-27.	1.3	36

#	Article	IF	Citations
523	Chemotherapy for older patients with prostate cancer. BJU International, 2007, 99, 269-273.	1.3	23
524	Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU International, 2007, 99, 274-280.	1.3	56
525	INTERMITTENT CHEMOTHERAPY IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE CANCER. BJU International, 2007, 100, 490-492.	1.3	9
526	Chemotherapy for Metastatic or Unresectable Bladder Cancer. Seminars in Oncology, 2007, 34, 135-144.	0.8	23
527	Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2005, 23, 2521-2533.	0.8	25
528	Overview of gemcitabine triplets in metastatic bladder cancer. Critical Reviews in Oncology/Hematology, 2003, 45, 191-197.	2.0	10
529	Chemotherapy in Metastatic Urothelial Cancer. American Journal of Cancer, 2002, 1, 23-31.	0.4	1
530	Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer, 2002, 95, 751-757.	2.0	133
531	New chemotherapy combinations for advanced bladder cancer. Current Opinion in Urology, 2001, 11, 517-522.	0.9	9
532	Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma. Cancer, 1998, 82, 878-885.	2.0	2
533	Frequent Dose Delays and Growth Factor Requirements with the Sequential Doxorubicin-CMF Schedule. Acta OncolÃ³gica, 1997, 36, 701-704.	0.8	2
534	Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. , 1997, 80, 1966-1972.		221
535	Early Results of the Value of p53 in Predicting Survival in a Homogeneous Cohort of Patients with Invasive Bladder Cancer Treated with a Neoadjuvant Carboplatin-Based Regimen (M-CAVI). Tumori, 1996, 82, 554-559.	0.6	3
536	Endobronchial metastatic disease: Analysis of 32 cases. , 1996, 62, 249-252.		103
537	Endobronchial metastatic disease: Analysis of 32 cases. Journal of Surgical Oncology, 1996, 62, 249-252.	0.8	2
538	Malignant Lymphoproliferative Diseases in HIV-Seropositive Patients: A study of 40 cases at a single institution in Spain. Acta OncolÃ³gica, 1995, 34, 75-82.	0.8	6
539	Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer, 1995, 75, 831-835.	2.0	15
540	Late recurrent metastasis in Wilms' tumour. Medical and Pediatric Oncology, 1994, 23, 158-161.	1.0	14

#	Article	IF	Citations
541	Diagnostic Value of Bronchoalveolar Lavage in Peripheral Lung Cancer. The American Review of Respiratory Disease, 1993, 147, 649-652.	2.9	69
542	Cytologic Diagnosis in Bronchoalveolar Lavage Specimens. Chest, 1990, 98, 513-514.	0.4	11
543	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. SSRN Electronic Journal, 0, , .	0.4	9